Expression of Bc-l2 in precancerous endometrial lesion and endometrial carcinoma | ||||
| Sohag Medical Journal | ||||
| Article 14, Volume 23, Issue 1, January 2019, Page 44-49 PDF (346.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2019.40957 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Walaa Abd El-Mohsen Hassan1; Mohamed Arafa Adly2; Ahmed Ahmed 3
| ||||
| 1Department of Zoology, Faculty of Science,Sohag University. | ||||
| 2Department of Zoology, Faculty of Science, Sohag University. | ||||
| 3Department of Pathology ,Faculty of Medicine, Sohag University. | ||||
| Abstract | ||||
| The oncogene Bcl-2 is known as a unique gene that plays an important role in the carcinogenesis pathway by blocking apoptosis. Aims: To evaluate the expression of Bcl-2 protein in normal, hyperplastic and neoplastic endometrial tissues. Materials and methods: Eighty three cases including 7 cases of normal endometrial changes, 37 cases of endometrial hyperplasia and 39 cases of endometrial adenocarcinoma were enrolled for this study. The expression of Bcl-2, ER and PR was evaluated by immunohistochemistry using streptavidin-biotin technique. Results: Non-malignant endometrial lesions tend to express significantly higher level of Bc-l2 compared to malignant endometrial lesion(p= 0.014). The expression of glandular Bc-l2 was significantly higher in hyperplasia compared to carcinoma(p=0.006).There was no significant association between Bcl-2 expression and tumors` histological type or stage orgrade. There was a correlation between Bcl-2 expression and ER or PR expression in endometrial carcinoma. Conclusions: Bcl-2 expression might represent a key in understanding the progression of endometrial neoplastic lesions. | ||||
| Keywords | ||||
| Endometrial carcinoma; Endometrial hyperplasia; Bcl-2; Er; PR | ||||
|
Supplementary Files
|
||||
| References | ||||
|
1. Jemal, A., R. Siegel, and E. Ward, Cancer statistics. Annals of Diagnostic Pathology, 2007. 11: p. 297–311.
2. Monika, P., et al., Estrogen Receptor βΔ6 (ERβΔ6) Isoform in Human Endometrial Hyperplasia and Adenocarcinoma. CANCER INVESTIGATION, 2004. 22: p. 211–218.
3. Sara, M.E.O., et al., Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem, 2004. 11(8): p. 1031-1039.
4. Osford, S., et al., Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr. Med. Chem., 2004. 11(8): p. 1031-1039.
5. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, Bcl-2 family members and the mitochondria in apoptosis. Genes Dev, 1999. 13: p. 1899-1911.
6. Wang, T. and J. Phang, Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 1995. 55: p. 2487-2489.
7. Morsi, H.M., et al., The Patterns of Expression of an Apoptosis-Related CK18 Neoepitope, the Bcl-2 Proto-Oncogene, and the Ki67 Proliferation Marker in Normal, Hyperplastic, and Malignant Endometrium. Journal of Gynecological Pathology, 2000. 19: p. 118-126.
8. Ahmed, R.H., et al., TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease. The American Journal of Pathology, 2012. 180(3): p. 904-916.
9. Mourizikou, A., et al., The use of an immunocytochemical double-labellingstaining can display the distribution of Bcl-2/Ki-67 cells in endome-trial adenocarcinoma as well as in normal endometrium. Clin. Lab., 2012. 58: p. 133-144.
10. Mora, L., et al., Differential diagnosis of endometrial hyperplasia and carcinoma by computerized imagecytometry of cell proliferation, apoptosis and Bcl-2 expression. Ann. Clin. Lab. Sci., 1999. 29: p. 308–315.
11. Laban, M., et al., Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis. Journal of Microscopy and Ultrastructure, 2015. 3: p. 19-24.
12. Erkanli, S., et al., Bcl-2 and P53 expression in endometrial carcinoma. J. Exp. Clin. Cancer Res. , 2004. 23: p. 97–103.
13. Kounelis, S., N. Kapranos, and E.e.a. Kouri, Immunohistochemical prolfile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod. Pathol. , 2000. 13: p. 379-388.
14. Appel, M., M. Edelweis, and J.e.a. Fleck, P53 and Bcl-2 as prognostic markers in endometrial carcinoma. Pathol. Oncol. Res., 2008. 14: p. 23-30.
15. Saegusa, M., et al., Bcl‐2 expression is correlated with a low apoptotic index and associated with progestrone receptor immunoreactivity in endometrial carcinomas The Journal of pathology, 1996. 180(3): p. 275-282.
16. Amalinei, C., et al., Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium Annals of Anatomy 2011. 193 p. 43–55.
17. Sivridis, E., A. Giatromaanolaki, and M.e.a. Koukourakis, Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and Bcl-2 expression. Virchows Arch., 2001. 438: p. 470-477.
18. Yamauchi, N., et al., Immunohistochemical analysis of endometrial adenocarcinoma for Bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity Int J. Gynecol Pathol., 1996. 15: p. 202–208.
| ||||
|
Statistics Article View: 326 PDF Download: 374 |
||||
